GKOS Glaukos Corporation

238.10USD+2.15%Mkt Cap: 14.09B USDP/E: —

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It off…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap14.09B USD
Enterprise Value13.86B USD
Revenue (TTM)690.33M USD
Gross Profit282.76M USD
Net Income (TTM)-187.69M USD
Revenue/Share11.83 USD
Last Price238.10 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees1.1K
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)170.07
PEG—
EV/EBITDA-692.41
EV/Revenue20.07
P/S20.42
P/B19.64
EPS (TTM)-2.95 USD
EPS (Forward)1.40 USD
52W Range
87.3290% of range255.18
52W High255.18 USD
52W Low87.32 USD
Profitability
Gross Margin55.72%
Oper. Margin-8.95%
EBITDA Margin-2.90%
Profit Margin-36.99%
ROE-28.60%
ROA-21.01%
ROIC-40.32%
ROCE-25.20%
Growth
Revenue Growth58.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.79M USD
CapEx (TTM)24.27M USD
FCF Margin7.62%
FCF Yield0.37%
Net Debt-231.55M USD
Net Debt/EBITDA11.57
Net Debt/FCF-4.40
Balance Sheet
Debt/Equity0.16
Current Ratio4.57
Quick Ratio3.84
Book Value/Sh12.12 USD
Cash/Share5.69 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)243.85 USD
Upside (mean)+2.4%
Target Range225.00 USD – 270.00 USD
225.00+2.4% to mean270.00
# Analysts13
Ownership
Shares Out.59.20M
Float57.05M
Insiders3.60%
Institutions103.59%
Short Interest
Short Ratio3.4d
Short % Float9.17%
Short % Out.7.57%
Shares Short4.48M
Short (prev mo.)3.85M
Technical
SMA 50188.19 (+26.5%)
SMA 200149.10 (+59.7%)
Beta0.68
S&P 52W Chg12.00%
Avg Vol (30d)1.53M
Avg Vol (10d)993.28K
Technical Indicators
RSI (14)61.7
MACD15.8177
MACD Signal17.0883
MACD Hist.-1.2706
BB Upper276.88 USD
BB Middle226.79 USD
BB Lower176.69 USD
BB Width44.18%
ATR (14)11.32 USD
Vol Ratio (20d)0.39x

About Glaukos (NYSE: GKOS)

›

Glaukos (NYSE: GKOS) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 1,094 employees.

The shares were at 238.10 USD on 19 November 2026, up 164.5% over 52 weeks. Its 52-week range is 87.32 USD to 255.18 USD: the price is 6.7% below the high and 172.7% above the low.

Its market capitalisation is 14.09B USD.

Glaukos reports return on equity of -28.6%, an operating margin of -9.0% and revenue up 58.0% year over year.

It holds more cash than debt, a net cash position of 231.55M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 13 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 243.85 USD is 2.4% above the current price. The next earnings report is expected on 16 February 2027.